Latest NR546 Final Exam: 100 Practice Questions &
Rationales (2026/2027 Update) chamberlain university
This comprehensive review guide is designed to prepare students for the NR546 Final Exam at
Chamberlain University, focusing on advanced psychopharmacology for the Psychiatric-Mental
Health Nurse Practitioner (PMHNP). The questions address key concepts in neuropharmacology,
pharmacodynamics, pharmacokinetics, and the clinical application of psychotropic medications
for psychiatric disorders across the lifespan . This guide aligns with the latest 2026/2027 exam
blueprints .
SECTION 1: NEUROPHARMACOLOGY AND RECEPTOR MECHANISMS (Q1-15)
Question 1
A 34-year-old woman with major depressive disorder has been prescribed an SSRI that
selectively blocks the serotonin transporter. The nurse practitioner understands that the
therapeutic effect of SSRIs is mediated through which downstream cellular mechanism?
A. Direct agonist at postsynaptic 5-HT2A receptors in the prefrontal cortex
B. Inhibition of monoamine oxidase type A in the presynaptic terminal
C. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased serotonergic
neurotransmission
D. Blockade of serotonin reuptake at the postsynaptic membrane
C. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased
serotonergic neurotransmission
RATIONALE: SSRIs block the serotonin transporter (SERT), increasing synaptic
serotonin. Initially, presynaptic 5-HT1A autoreceptors limit serotonin release, but with chronic
treatment (2-4 weeks), these autoreceptors desensitize, allowing full enhancement of
serotonergic neurotransmission. This delayed desensitization explains the therapeutic lag of
SSRIs .
Question 2
A 42-year-old man with schizophrenia has elevated prolactin levels causing gynecomastia and
galactorrhea. His current antipsychotic medication is known to block dopamine D2 receptors in
the tuberoinfundibular pathway. Which mechanism explains the hyperprolactinemia?
A. Histamine H1 receptor antagonism increases prolactin synthesis
B. Serotonin reuptake inhibition increases prolactin-releasing hormone
,C. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory tone
D. Dopamine stimulates prolactin release; D2 blockade enhances pituitary function
C. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory
tone
RATIONALE: In the tuberoinfundibular pathway, dopamine acts as a prolactin-inhibiting
factor (PIF) by binding to D2 receptors on lactotroph cells in the anterior pituitary. When
antipsychotics block these D2 receptors, the inhibitory tone on prolactin secretion is removed,
leading to hyperprolactinemia and its clinical consequences .
Question 3
A psychiatric nurse practitioner is teaching a patient about the blood-brain barrier and
psychotropic drug delivery. Lipophilicity of a medication most directly determines which
pharmacokinetic property?
A. Affinity for receptor binding sites on postsynaptic membranes
B. Duration of action in the synaptic cleft before reuptake
C. Ability to cross the blood-brain barrier and reach central nervous system targets
D. Rate of hepatic metabolism by cytochrome P450 enzymes
C. Ability to cross the blood-brain barrier and reach central nervous system targets
RATIONALE: The blood-brain barrier consists of endothelial tight junctions that restrict
paracellular transport. Lipophilic (fat-soluble) drugs can passively diffuse through the
endothelial cell membranes of the BBB, while hydrophilic drugs cannot. Most antipsychotic
medications are designed to be lipophilic to ensure adequate CNS penetration .
Question 4
Which receptor partial agonism underlies vilazodone's lower incidence of SSRI-type sexual
dysfunction?
A. 5-HT2C
B. 5-HT1D
C. 5-HT1A
D. 5-HT3
C. 5-HT1A
RATIONALE: Vilazodone is an SSRI + 5-HT1A partial agonist; presynaptic 5-HT1A
desensitization accelerates serotonin firing and reduces sexual side effects compared to pure
SSRIs .
,Question 5
A CYP2D6 ultra-rapid metabolizer is started on aripiprazole 10 mg daily. What is the expected
clinical outcome?
A. Increased akathisia
B. Prolonged QT
C. Sub-therapeutic response
D. Elevated drug levels
C. Sub-therapeutic response
RATIONALE: Aripiprazole is a 2D6 substrate; ultra-rapid metabolizers convert parent drug
to active metabolite (dehydro-aripiprazole) faster, lowering steady-state levels and potentially
leading to subtherapeutic response .
Question 6
A 28-year-old patient with bipolar disorder is prescribed a medication that blocks voltage-gated
sodium channels and inhibits glutamate release. This mechanism of action is most consistent
with which medication?
A. Lithium carbonate
B. Valproic acid
C. Carbamazepine
D. Lamotrigine
D. Lamotrigine
RATIONALE: Lamotrigine blocks voltage-gated sodium channels, stabilizing neuronal
membranes and inhibiting glutamate release. This mechanism contributes to its mood-stabilizing
effects, particularly in bipolar depression .
Question 7
Name the glutamate receptor subtype whose antagonism produces the rapid-acting antidepressant
effect of intranasal esketamine.
A. AMPA
B. NMDA
C. Kainate
D. Metabotropic
B. NMDA
, RATIONALE: NMDA receptor antagonism on GABAergic interneurons leads to
disinhibition of glutamate burst, AMPA activation, BDNF release, and synaptogenesis. This
mechanism underlies the rapid-acting antidepressant effect of esketamine .
Question 8
A patient's lithium level 10 hours post-dose is 1.3 mmol/L (target 0.8-1.0). Patient has eGFR 55
mL/min/1.73 m², sodium 134 mmol/L, and is on HCTZ 25 mg. What is the next step?
A. Add amiloride
B. Switch to Depakote
C. Reduce lithium dose by 25% and repeat level in 5 days
D. Stop HCTZ immediately
C. Reduce lithium dose by 25% and repeat level in 5 days
RATIONALE: Thiazide diuretics decrease sodium delivery, increasing lithium reabsorption
and potentially causing toxicity. Dose reduction is the safest approach; stopping HCTZ abruptly
may cause rebound hypertension .
Question 9
The therapeutic effect of antipsychotics for positive symptoms of schizophrenia is primarily
achieved through:
A. D2 receptor antagonism in the mesolimbic pathway
B. D2 receptor antagonism in the nigrostriatal pathway
C. 5-HT2A receptor antagonism
D. D2 receptor antagonism in the tuberoinfundibular pathway
A. D2 receptor antagonism in the mesolimbic pathway
RATIONALE: Positive symptoms (hallucinations, delusions) are caused by excessive
dopamine activity in the mesolimbic pathway. Antipsychotics block D2 receptors in this pathway
to reduce symptoms. The nigrostriatal pathway is associated with extrapyramidal symptoms, and
the tuberoinfundibular pathway is associated with prolactin elevation .
Question 10
Which antipsychotic has the LOWEST peak-to-trough fluctuation when given as a long-acting
injectable (LAI)?
A. Haloperidol decanoate
B. Paliperidone palmitate once-monthly
Rationales (2026/2027 Update) chamberlain university
This comprehensive review guide is designed to prepare students for the NR546 Final Exam at
Chamberlain University, focusing on advanced psychopharmacology for the Psychiatric-Mental
Health Nurse Practitioner (PMHNP). The questions address key concepts in neuropharmacology,
pharmacodynamics, pharmacokinetics, and the clinical application of psychotropic medications
for psychiatric disorders across the lifespan . This guide aligns with the latest 2026/2027 exam
blueprints .
SECTION 1: NEUROPHARMACOLOGY AND RECEPTOR MECHANISMS (Q1-15)
Question 1
A 34-year-old woman with major depressive disorder has been prescribed an SSRI that
selectively blocks the serotonin transporter. The nurse practitioner understands that the
therapeutic effect of SSRIs is mediated through which downstream cellular mechanism?
A. Direct agonist at postsynaptic 5-HT2A receptors in the prefrontal cortex
B. Inhibition of monoamine oxidase type A in the presynaptic terminal
C. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased serotonergic
neurotransmission
D. Blockade of serotonin reuptake at the postsynaptic membrane
C. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased
serotonergic neurotransmission
RATIONALE: SSRIs block the serotonin transporter (SERT), increasing synaptic
serotonin. Initially, presynaptic 5-HT1A autoreceptors limit serotonin release, but with chronic
treatment (2-4 weeks), these autoreceptors desensitize, allowing full enhancement of
serotonergic neurotransmission. This delayed desensitization explains the therapeutic lag of
SSRIs .
Question 2
A 42-year-old man with schizophrenia has elevated prolactin levels causing gynecomastia and
galactorrhea. His current antipsychotic medication is known to block dopamine D2 receptors in
the tuberoinfundibular pathway. Which mechanism explains the hyperprolactinemia?
A. Histamine H1 receptor antagonism increases prolactin synthesis
B. Serotonin reuptake inhibition increases prolactin-releasing hormone
,C. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory tone
D. Dopamine stimulates prolactin release; D2 blockade enhances pituitary function
C. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory
tone
RATIONALE: In the tuberoinfundibular pathway, dopamine acts as a prolactin-inhibiting
factor (PIF) by binding to D2 receptors on lactotroph cells in the anterior pituitary. When
antipsychotics block these D2 receptors, the inhibitory tone on prolactin secretion is removed,
leading to hyperprolactinemia and its clinical consequences .
Question 3
A psychiatric nurse practitioner is teaching a patient about the blood-brain barrier and
psychotropic drug delivery. Lipophilicity of a medication most directly determines which
pharmacokinetic property?
A. Affinity for receptor binding sites on postsynaptic membranes
B. Duration of action in the synaptic cleft before reuptake
C. Ability to cross the blood-brain barrier and reach central nervous system targets
D. Rate of hepatic metabolism by cytochrome P450 enzymes
C. Ability to cross the blood-brain barrier and reach central nervous system targets
RATIONALE: The blood-brain barrier consists of endothelial tight junctions that restrict
paracellular transport. Lipophilic (fat-soluble) drugs can passively diffuse through the
endothelial cell membranes of the BBB, while hydrophilic drugs cannot. Most antipsychotic
medications are designed to be lipophilic to ensure adequate CNS penetration .
Question 4
Which receptor partial agonism underlies vilazodone's lower incidence of SSRI-type sexual
dysfunction?
A. 5-HT2C
B. 5-HT1D
C. 5-HT1A
D. 5-HT3
C. 5-HT1A
RATIONALE: Vilazodone is an SSRI + 5-HT1A partial agonist; presynaptic 5-HT1A
desensitization accelerates serotonin firing and reduces sexual side effects compared to pure
SSRIs .
,Question 5
A CYP2D6 ultra-rapid metabolizer is started on aripiprazole 10 mg daily. What is the expected
clinical outcome?
A. Increased akathisia
B. Prolonged QT
C. Sub-therapeutic response
D. Elevated drug levels
C. Sub-therapeutic response
RATIONALE: Aripiprazole is a 2D6 substrate; ultra-rapid metabolizers convert parent drug
to active metabolite (dehydro-aripiprazole) faster, lowering steady-state levels and potentially
leading to subtherapeutic response .
Question 6
A 28-year-old patient with bipolar disorder is prescribed a medication that blocks voltage-gated
sodium channels and inhibits glutamate release. This mechanism of action is most consistent
with which medication?
A. Lithium carbonate
B. Valproic acid
C. Carbamazepine
D. Lamotrigine
D. Lamotrigine
RATIONALE: Lamotrigine blocks voltage-gated sodium channels, stabilizing neuronal
membranes and inhibiting glutamate release. This mechanism contributes to its mood-stabilizing
effects, particularly in bipolar depression .
Question 7
Name the glutamate receptor subtype whose antagonism produces the rapid-acting antidepressant
effect of intranasal esketamine.
A. AMPA
B. NMDA
C. Kainate
D. Metabotropic
B. NMDA
, RATIONALE: NMDA receptor antagonism on GABAergic interneurons leads to
disinhibition of glutamate burst, AMPA activation, BDNF release, and synaptogenesis. This
mechanism underlies the rapid-acting antidepressant effect of esketamine .
Question 8
A patient's lithium level 10 hours post-dose is 1.3 mmol/L (target 0.8-1.0). Patient has eGFR 55
mL/min/1.73 m², sodium 134 mmol/L, and is on HCTZ 25 mg. What is the next step?
A. Add amiloride
B. Switch to Depakote
C. Reduce lithium dose by 25% and repeat level in 5 days
D. Stop HCTZ immediately
C. Reduce lithium dose by 25% and repeat level in 5 days
RATIONALE: Thiazide diuretics decrease sodium delivery, increasing lithium reabsorption
and potentially causing toxicity. Dose reduction is the safest approach; stopping HCTZ abruptly
may cause rebound hypertension .
Question 9
The therapeutic effect of antipsychotics for positive symptoms of schizophrenia is primarily
achieved through:
A. D2 receptor antagonism in the mesolimbic pathway
B. D2 receptor antagonism in the nigrostriatal pathway
C. 5-HT2A receptor antagonism
D. D2 receptor antagonism in the tuberoinfundibular pathway
A. D2 receptor antagonism in the mesolimbic pathway
RATIONALE: Positive symptoms (hallucinations, delusions) are caused by excessive
dopamine activity in the mesolimbic pathway. Antipsychotics block D2 receptors in this pathway
to reduce symptoms. The nigrostriatal pathway is associated with extrapyramidal symptoms, and
the tuberoinfundibular pathway is associated with prolactin elevation .
Question 10
Which antipsychotic has the LOWEST peak-to-trough fluctuation when given as a long-acting
injectable (LAI)?
A. Haloperidol decanoate
B. Paliperidone palmitate once-monthly
